Notch signaling in female cancers: a multifaceted node to overcome drug resistance

Abstract

Drug resistance is one of the main challenges in cancer therapy, including in the treatment of female-specific malignancies, which account for more than 60% of cancer cases among women. Therefore, elucidating the underlying molecular mechanisms is an urgent need in gynecological cancers to foster novel therapeutic approaches. Notably, Notch signaling, including either receptors or ligands, has emerged as a promising candidate given its multifaceted role in almost all of the hallmarks of cancer. Concerning the connection between Notch pathway and drug resistance in the afore-mentioned tumor contexts, several studies focused on the Notch-dependent regulation of the cancer stem cell (CSC) subpopulation or the induction of the epithelial-to-mesenchymal transition (EMT), both features implicated in either intrinsic or acquired resistance. Indeed, the present review provides an up-to-date overview of the published results on Notch signaling and EMT- or CSC-driven drug resistance. Moreover, other drug resistance-related mechanisms are examined such as the involvement of the Notch pathway in drug efflux and tumor microenvironment. Collectively, there is a long way to go before every facet will be fully understood; nevertheless, some small pieces are falling neatly into place. Overall, the main aim of this review is to provide strong evidence in support of Notch signaling inhibition as an effective strategy to evade or reverse resistance in female-specific cancers.

Keywords

Notch signaling / drug resistance / female-specific cancers / cancer stem cells / epithelial-to-mesenchymal transition / drug efflux / tumor microenvironment

References

[1] Torre LA,Siegel RL,Jemal A.Global cancer in women: burden and trends.Cancer Epidemiol Biomarkers Prev2017;26:444-57

[2] Luque-Bolivar A,Villegas VE.Resistance and overcoming resistance in breast cancer.Breast Cancer (Dove Med Press)2020;12:211-29 PMCID:PMC7666993

[3] Pinato DJ,Gabra H.Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance.Cancer Treat Rev2013;39:153-60

[4] Holohan C,Longley DB.Cancer drug resistance: an evolving paradigm.Nat Rev Cancer2013;13:714-26

[5] Vasan N,Hyman DM.A view on drug resistance in cancer.Nature2019;575:299-309 PMCID:PMC8008476

[6] Haider T,Banjare N,Soni V.Drug resistance in cancer: mechanisms and tackling strategies.Pharmacol Rep2020;72:1125-51

[7] Bukowski K,Kontek R.Mechanisms of multidrug resistance in cancer chemotherapy.Int J Mol Sci2020;21:3233 PMCID:PMC7247559

[8] Giuli MV,Screpanti I,Checquolo S.Notch signaling activation as a Hallmark for triple-negative breast cancer subtype.J Oncol2019;2019:8707053 PMCID:PMC6657611

[9] Orzechowska M,Bednarek AK.Functional gene expression differentiation of the notch signaling pathway in female reproductive tract tissues-A comprehensive review with analysis.Front Cell Dev Biol2020;8:592616 PMCID:PMC7770115

[10] Druesne-Pecollo N,Barrandon E.Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies.Breast Cancer Res Treat2012;135:647-54

[11] Youlden DR,Dunn NA,Pyke CM.The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality.Cancer Epidemiol2012;36:237-48

[12] Hortobagyi GN,Pritchard K.ABREAST InvestigatorsThe global breast cancer burden: variations in epidemiology and survival.Clin Breast Cancer2005;6:391-401

[13] Allemani C,Carreira H.Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2).Lancet2015;385:977-1010 PMCID:PMC4588097

[14] Toriola AT.Trends in breast cancer incidence and mortality in the United States: implications for prevention.Breast Cancer Res Treat2013;138:665-73

[15] Anastasiadi Z,Ignatiadou E,Mitsis M.Breast cancer in young women: an overview.Updates Surg2017;69:313-7

[16] Anders CK,Broadwater G.Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.J Clin Oncol2008;26:3324-30

[17] Anderson WF,Ershler WB.Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database.Breast Cancer Res Treat2002;76:27-36

[18] Cadoo KA.Biological subtypes of breast cancer: current concepts and implications for recurrence patterns.Q J Nucl Med Mol Imaging2013;57:312-21

[19] Morris PG,Mallam D.Limited overall survival in patients with brain metastases from triple negative breast cancer.Breast J2012;18:345-50

[20] Morris GJ,Topham AK.Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database.Cancer2007;110:876-84

[21] Stevanovic A,Wilcken N.Metastatic breast cancer.Aust Fam Physician2006;35:309-12

[22] Colditz GA.Priorities for the primary prevention of breast cancer.CA Cancer J Clin2014;64:186-94

[23] Ellis MJ,Hoog J.Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance).J Clin Oncol2017;35:1061-9 PMCID:PMC5455353

[24] Benson AB 3rd,Somerfield MR.American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.J Clin Oncol2004;22:3408-19

[25] McDonald ES,Tchou J,Freedman GM.Clinical diagnosis and management of breast cancer.J Nucl Med2016;57 Suppl 1:9S-16S

[26] Fredholm H,Frisell J,Fredriksson I.Breast cancer in young women: poor survival despite intensive treatment.PLoS One2009;4:e7695 PMCID:PMC2770847

[27] Vargas AN.Natural history of ovarian cancer.Ecancermedicalscience2014;8:465 PMCID:PMC4176445

[28] Reid BM,Sellers TA.Epidemiology of ovarian cancer: a review.Cancer Biol Med2017;14:9-32 PMCID:PMC5365187

[29] Siegel RL,Jemal A.Cancer statistics, 2016.CA Cancer J Clin2016;66:7-30

[30] Matulonis UA,Fallowfield L,Sehouli J.Ovarian cancer.Nat Rev Dis Primers2016;2:16061 PMCID:PMC7290868

[31] Torre LA,Siegel RL,Lortet-Tieulent J.Global cancer statistics, 2012.CA Cancer J Clin2015;65:87-108

[32] Jayson GC,Kitchener HC.Ovarian cancer.Lancet2014;384:1376-88

[33] Beral V,Peto R.Hormone therapy and ovarian cancer - Authors' reply.Lancet2015;386:1038-9

[34] Armstrong DK,Wenzel L.Gynecologic Oncology GroupIntraperitoneal cisplatin and paclitaxel in ovarian cancer.N Engl J Med2006;354:34-43

[35] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018;68:394-424

[36] Ferlay J,Dikshit R.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.Int J Cancer2015;136:E359-86

[37] Jansen EEL,Gini A.EU-TOPIA consortiumEffect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review.Eur J Cancer2020;127:207-23

[38] Waggoner SE.Cervical cancer.Lancet2003;361:2217-25

[39] Olorunfemi G,Masukume G,Pisa PT.Temporal trends in the epidemiology of cervical cancer in South Africa (1994-2012).Int J Cancer2018;143:2238-49 PMCID:PMC6195436

[40] Villain P,Almonte M.European code against cancer 4th edition: infections and cancer.Cancer Epidemiol2015;39 Suppl 1:S120-38

[41] de Sanjosé S,Castellsagué X.Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis.Lancet Infect Dis2007;7:453-9

[42] Moscicki AB,Burchell A.Updating the natural history of human papillomavirus and anogenital cancers.Vaccine2012;30 Suppl 5:F24-33 PMCID:PMC3700362

[43] Maza M,Bergman KL,Cremer ML.Cervical precancer treatment in low- and middle-income countries: a technology overview.J Glob Oncol2017;3:400-8 PMCID:PMC5560450

[44] Cohen PA,Oaknin A.Cervical cancer.Lancet2019;393:169-82

[45] Marquina G,Casado A.Targeted agents in cervical cancer: beyond bevacizumab.Curr Oncol Rep2018;20:40

[46] De Angelis R,Coleman MP.Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study.Lancet Oncol2014;15:23-34

[47] El Mistiri M,Marcheselli L.Cancer incidence, mortality, and survival in Eastern Libya: updated report from the Benghazi Cancer Registry.Ann Epidemiol2015;25:564-8

[48] Arnold M,Byrnes G.Global burden of cancer attributable to high body-mass index in 2012: a population-based study.Lancet Oncol2015;16:36-46 PMCID:PMC4314462

[49] Cook LS,Magliocco AM.Endometrial cancer survival among U.S. black and white women by birth cohort.Epidemiology2006;17:469-72

[50] Syeda S,Hou JY.Chemotherapy, radiation, or combination therapy for stage III uterine cancer.Obstet Gynecol2019;134:17-29 PMCID:PMC6594914

[51] Brasseur K,Asselin E.Chemoresistance and targeted therapies in ovarian and endometrial cancers.Oncotarget2017;8:4008-42 PMCID:PMC5354810

[52] Artavanis-Tsakonas S,Lake RJ.Notch signaling: cell fate control and signal integration in development.Science1999;284:770-6

[53] Blaumueller CM,Zagouras P.Intracellular cleavage of notch leads to a heterodimeric receptor on the plasma membrane.Cell1997;90:281-91

[54] Hori K,Artavanis-Tsakonas S.Notch signaling at a glance.J Cell Sci2013;126:2135-40 PMCID:PMC3672934

[55] Bray SJ.Notch signalling: a simple pathway becomes complex.Nat Rev Mol Cell Biol2006;7:678-89

[56] Suresh S.The NOTCH signaling pathway in normal and malignant blood cell production.J Cell Commun Signal2015;9:5-13 PMCID:PMC4414835

[57] D'Souza B,Weinmaster G.The many facets of Notch ligands.Oncogene2008;27:5148-67 PMCID:PMC2791526

[58] Groot AJ.The role of Adams in Notch signaling. In: Reichrath J, Reichrath S, editors. Notch signaling in embryology and cancer. New York: Springer US; 2012. p. 15-36.

[59] Yang G,Zhou Q.Structural basis of Notch recognition by human γ-secretase.Nature2019;565:192-7

[60] Tien AC,Bellen HJ.A Notch updated.J Cell Biol2009;184:621-9 PMCID:PMC2686403

[61] Kitagawa M.Notch signalling in the nucleus: roles of Mastermind-like (MAML) transcriptional coactivators.J Biochem2016;159:287-94

[62] Contreras-Cornejo H,Oviedo-Boyso J.The CSL proteins, versatile transcription factors and context dependent corepressors of the notch signaling pathway.Cell Div2016;11:12 PMCID:PMC5037638

[63] Schwanbeck R,Bernoth K.The Notch signaling pathway: molecular basis of cell context dependency.Eur J Cell Biol2011;90:572-81

[64] Siebel C.Notch signaling in development, tissue homeostasis, and disease.Physiol Rev2017;97:1235-94

[65] Aster JC,Blacklow SC.The varied roles of notch in cancer.Annu Rev Pathol2017;12:245-75 PMCID:PMC5933931

[66] Lobry C,Aifantis I.Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think.J Exp Med2011;208:1931-5 PMCID:PMC3182047

[67] Ranganathan P,Capobianco AJ.Notch signalling in solid tumours: a little bit of everything but not all the time.Nat Rev Cancer2011;11:338-51

[68] Weng AP,Lee W.Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.Science2004;306:269-71

[69] Braune EB,Lendahl U.Notch and Wnt dysregulation and its relevance for breast cancer and tumor initiation.Biomedicines2018;6:101 PMCID:PMC6315509

[70] Groeneweg JW,Growdon WB,Rueda BR.Notch signaling in serous ovarian cancer.J Ovarian Res2014;7:95 PMCID:PMC4228063

[71] Shang C,Meng LR.Blocking NOTCH pathway can enhance the effect of EGFR inhibitor through targeting CD133+ endometrial cancer cells.Cancer Biol Ther2018;19:113-9 PMCID:PMC5790374

[72] Wang L,Yang J,Zhang W.Cervical cancer cell growth, drug resistance, and epithelial-mesenchymal transition are suppressed by y-secretase inhibitor RO4929097.Med Sci Monit2018;24:4046-53 PMCID:PMC6032799

[73] Batlle E.Cancer stem cells revisited.Nat Med2017;23:1124-34

[74] Lytle NK,Reya T.Stem cell fate in cancer growth, progression and therapy resistance.Nat Rev Cancer2018;18:669-80

[75] Najafi M,Majidpoor J.Cancer stem cell (CSC) resistance drivers.Life Sci2019;234:116781

[76] Shibue T.EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.Nat Rev Clin Oncol2017;14:611-29 PMCID:PMC5720366

[77] Keyvani V,Esmaeili SA.Ovarian cancer stem cells and targeted therapy.J Ovarian Res2019;12:120 PMCID:PMC6896744

[78] Li Y,Ajani JA.Drug resistance and Cancer stem cells.Cell Commun Signal2021;19:19 PMCID:PMC7885480

[79] Abdullah LN.Mechanisms of chemoresistance in cancer stem cells.Clin Transl Med2013;2:3 PMCID:PMC3565873

[80] Tanabe S,Cabral H.Interplay of EMT and CSC in cancer and the potential therapeutic strategies.Front Pharmacol2020;11:904 PMCID:PMC7311659

[81] Yang Y,Wang T,Xi T.Emerging agents that target signaling pathways in cancer stem cells.J Hematol Oncol2020;13:60 PMCID:PMC7249421

[82] Takebe N,Ivy SP.Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition.Breast Cancer Res2011;13:211 PMCID:PMC3218933

[83] Muñoz-Galván S,García-Carrasco M.New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.J Exp Clin Cancer Res2019;38:234 PMCID:PMC6547556

[84] Meisel CT,Mitsiadis TA.Cancer stem cells, Quo Vadis?.Cells2020;9:1879 PMCID:PMC7463613

[85] BeLow M.Notch signaling in breast cancer: a role in drug resistance.Cells2020;9:2204 PMCID:PMC7601482

[86] Acar A,Clarke RB.A role for Notch signalling in breast cancer and endocrine resistance.Stem Cells Int2016;2016:2498764 PMCID:PMC4736972

[87] Nedeljković M.Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge.Cells2019;8:957 PMCID:PMC6770896

[88] Grudzien P,Albain KS.Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.Anticancer Res2010;30:3853-67

[89] Harrison H,Howell SJ.Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.Cancer Res2010;70:709-18 PMCID:PMC3442245

[90] Suman S,Damodaran C.Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells.Br J Cancer2013;109:2587-96 PMCID:PMC3833225

[91] Samanta D,Chaturvedi P,Semenza GL.Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.Proc Natl Acad Sci U S A2014;111:E5429-38 PMCID:PMC4273385

[92] Hajizadeh F,Esmaily M.Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells.Life Sci2019;237:116952

[93] Yan Y,Han L.HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways.J Exp Clin Cancer Res2018;37:256 PMCID:PMC6194720

[94] Wang T,Lee H.JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance.Cell Metab2018;27:1357 PMCID:PMC6116734

[95] Kim E,Woo DH.Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.Cancer Cell2013;23:839-52 PMCID:PMC4109796

[96] Yang Q,Shi Z.Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling.J Exp Clin Cancer Res2021;40:120 PMCID:PMC8022546

[97] Qiu M,Jiang I.Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells.Cancer Lett2013;328:261-70

[98] Rustighi A,Tiberi L.Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast.EMBO Mol Med2014;6:99-119 PMCID:PMC3936488

[99] Rodriguez D,Lin X,Major P.The central contributions of breast cancer stem cells in developing resistance to endocrine therapy in estrogen receptor (ER)-positive breast cancer.Cancers (Basel)2019;11:1028 PMCID:PMC6678134

[100] Simões BM,Eyre R.Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity.Cell Rep2015;12:1968-77 PMCID:PMC4594158

[101] McClements L,Yakkundi A.FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.BMC Cancer2019;19:351 PMCID:PMC6460676

[102] Diluvio G,Giuli MV.NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest.Oncogenesis2018;7:42 PMCID:PMC5968025

[103] Bousquet MS,Pope JL.Seaweed natural products modify the host inflammatory response via Nrf2 signaling and alter colon microbiota composition and gene expression.Free Radic Biol Med2020;146:306-23 PMCID:PMC7339024

[104] Chen Y,Gill GN.Regulation of the ERBB-2 promoter by RBPJkappa and NOTCH.J Biol Chem1997;272:14110-4

[105] Takebe N,Warren RQ.Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways.Nat Rev Clin Oncol2011;8:97-106

[106] Farnie G,Clarke RB.Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status.PLoS One2013;8:e56840 PMCID:PMC3572946

[107] Magnifico A,Campaner S.Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.Clin Cancer Res2009;15:2010-21

[108] Shah D,Baker AT.Inhibition of HER2 increases JAGGED1-dependent breast cancer stem cells: role for membrane JAGGED1.Clin Cancer Res2018;24:4566-78 PMCID:PMC6139046

[109] Osipo C,Rizzo P.ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.Oncogene2008;27:5019-32

[110] Baker A,Bocchetta M.Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival.Oncogene2018;37:4489-504

[111] Loibl S,Huober J.Integrated analysis of PTEN and p4EBP1 protein expression as predictors for pCR in HER2-positive breast cancer.Clin Cancer Res2016;22:2675-83

[112] Steelman LS,Sokolosky ML.Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.Oncogene2008;27:4086-95 PMCID:PMC3836277

[113] Revandkar A,Toso A.Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.Nat Commun2016;7:13719 PMCID:PMC5159884

[114] Steelman LS,Chappell WH.Akt as a therapeutic target in cancer.Expert Opin Ther Targets2008;12:1139-65

[115] Choi HJ,Park JY.A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.Gynecol Oncol2019;153:135-48

[116] Bhola NE,Koch JP.Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and Notch-dependent cancer stem cell population.Cancer Res2016;76:440-52 PMCID:PMC4715956

[117] Ghasemi F,Athari SS.Therapeutics strategies against cancer stem cell in breast cancer.Int J Biochem Cell Biol2019;109:76-81

[118] Song LL,Yun J.Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells.Oncogene2008;27:5833-44

[119] Hao L,Osipo C.Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.Oncogene2010;29:201-13 PMCID:PMC4976641

[120] Hossain F,Ucar DA.Notch signaling regulates mitochondrial metabolism and NF-κB activity in triple-negative breast cancer cells via IKKα-dependent non-canonical pathways.Front Oncol2018;8:575 PMCID:PMC6289043

[121] Mollen EWJ,Tjan-Heijnen VCG.Moving breast cancer therapy up a Notch.Front Oncol2018;8:518 PMCID:PMC6256059

[122] Locatelli MA,Dees EC.Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.Oncotarget2017;8:2320-8 PMCID:PMC5356802

[123] Zhang CC,Zong Q.Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.Stem Cells Transl Med2013;2:233-42 PMCID:PMC3659764

[124] Schott AF,Dontu G.Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.Clin Cancer Res2013;19:1512-24 PMCID:PMC3602220

[125] Smith DC,Patnaik A.A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors.Invest New Drugs2019;37:722-30 PMCID:PMC6647865

[126] Ceccarelli S,Bellavia D,Screpanti I.Notch3 targeting: a novel weapon against ovarian cancer stem cells.Stem Cells Int2019;2019:6264931 PMCID:PMC6339748

[127] Zhang L,Gao M.SNORA72 Activates the Notch1/c-Myc pathway to promote stemness transformation of ovarian cancer cells.Front Cell Dev Biol2020;8:583087 PMCID:PMC7669759

[128] Kakar SS,Wang Z,Ratajczak M.DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer.J Cancer Stem Cell Res2016;4:e1002 PMCID:PMC5033248

[129] Li Y,Zhu J,Jiang H.High ALDH activity defines ovarian cancer stem-like cells with enhanced invasiveness and EMT progress which are responsible for tumor invasion.Biochem Biophys Res Commun2018;495:1081-8

[130] Silva IA,McLean K.Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.Cancer Res2011;71:3991-4001 PMCID:PMC3107359

[131] Kim MJ,Jeong JY.Correlation of ALDH1 and Notch3 expression: clinical implication in ovarian carcinomas.J Cancer2017;8:3331-42 PMCID:PMC5665050

[132] Kang H,Song JY.Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.Mol Carcinog2016;55:1196-209

[133] Jeong JY,Kim TH.MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.Cancer Lett2017;386:168-78

[134] McAuliffe SM,Wyant GA.Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.Proc Natl Acad Sci U S A2012;109:E2939-48 PMCID:PMC3491453

[135] Li H,Niu C.Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.Int J Cancer2019;145:1921-34 PMCID:PMC6767785

[136] Jiang LY,Du P.γ-secretase inhibitor, DAPT inhibits self-renewal and stemness maintenance of ovarian cancer stem-like cells in vitro.Chin J Cancer Res2011;23:140-6 PMCID:PMC3587542

[137] Liu L,Fang C,Feng Y.OCT4 mediates FSH-induced epithelial-mesenchymal transition and invasion through the ERK1/2 signaling pathway in epithelial ovarian cancer.Biochem Biophys Res Commun2015;461:525-32

[138] Zhang Z,Lai Y.Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway.Int J Oncol2013;43:1194-204 PMCID:PMC3981007

[139] Lee H,Choi DK.Poziotinib suppresses ovarian cancer stem cell growth via inhibition of HER4-mediated STAT5 pathway.Biochem Biophys Res Commun2020;526:158-64

[140] Kang HG,Kim SJ.Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain.Oncotarget2016;7:68229-41 PMCID:PMC5356551

[141] Islam SS.Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway.J Exp Clin Cancer Res2019;38:382 PMCID:PMC6716935

[142] Steg AD,Goodman B.Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.Clin Cancer Res2011;17:5674-85 PMCID:PMC3166981

[143] Liu Z,Li F.GATA1-regulated JAG1 promotes ovarian cancer progression by activating Notch signal pathway.Protoplasma2020;257:901-10

[144] Seo EJ,Jang IH.Hypoxia-NOTCH1-SOX2 signaling is important for maintaining cancer stem cells in ovarian cancer.Oncotarget2016;7:55624-38 PMCID:PMC5342441

[145] Wang K,Luo L.Identification of a cancer stem cell-like side population in the HeLa human cervical carcinoma cell line.Oncol Lett2013;6:1673-80 PMCID:PMC3833864

[146] Yang B,Zhang A.Correction: doxycycline induces apoptosis and inhibits proliferation and invasion of human cervical carcinoma stem cells.PLoS One2015;10:e0134201 PMCID:PMC4514786

[147] Nayak A,Nayak D,Narayan S.Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation.Cell Oncol (Dordr)2019;42:157-71

[148] Prabakaran DS,Sivaraman T,Park WY.Silencing of FTS increases radiosensitivity by blocking radiation-induced Notch1 activation and spheroid formation in cervical cancer cells.Int J Biol Macromol2019;126:1318-25

[149] Dean M,Bates S.Tumour stem cells and drug resistance.Nat Rev Cancer2005;5:275-84

[150] Friel AM,Curley MD.Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells.Reprod Biol Endocrinol2010;8:147 PMCID:PMC3027593

[151] Liu J,Huang J,Liu T.Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.Biochem Biophys Res Commun2014;444:670-5

[152] Nishimura T,Yamashita S,Kigure K.Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.BMC Cancer2015;15:957 PMCID:PMC4682234

[153] Nieto MA,Jackson RA.EMT: 2016.Cell2016;166:21-45

[154] Thiery JP.Tumor dissemination: an EMT affair.Cancer Cell2013;23:272-3

[155] Wang Z,Kong D.Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.Cancer Res2009;69:2400-7 PMCID:PMC2657919

[156] Saad S,Yong R,Pollock CA.Notch mediated epithelial to mesenchymal transformation is associated with increased expression of the Snail transcription factor.Int J Biochem Cell Biol2010;42:1115-22

[157] Kang J,Kim W.Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines.J Biol Chem2013;288:27343-57 PMCID:PMC3779729

[158] Chen J,Chen J.Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion.Br J Cancer2010;102:351-60 PMCID:PMC2816657

[159] Shao S,Zhang X.Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner.Mol Cancer2015;14:28 PMCID:PMC4322803

[160] Leong KG,Kulic I.Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin.J Exp Med2007;204:2935-48 PMCID:PMC2118507

[161] Lee GH,An Y.FYN promotes mesenchymal phenotypes of basal type breast cancer cells through STAT5/NOTCH2 signaling node.Oncogene2018;37:1857-68

[162] Elzamy S,Kandeel W.The prognostic significance of androgen receptor and β-catenin immunohistochemical expression in urothelial carcinoma with and without detrusor muscle invasion from an Egyptian institution.Pol J Pathol2018;69:234-42

[163] Sahlgren C,Jin S,Lendahl U.Notch signaling mediates hypoxia-induced tumor cell migration and invasion.Proc Natl Acad Sci U S A2008;105:6392-7 PMCID:PMC2359811

[164] Xiao YS,Liang YK.Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cells.Cancer Lett2019;440-441:156-67

[165] Scheffer GL,Flens MJ.The drug resistance-related protein LRP is the human major vault protein.Nat Med1995;1:578-82

[166] Han M,Tang XJ.Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.J Control Release2012;163:136-44

[167] Berger W,Grusch M,Micksche M.Vaults and the major vault protein: novel roles in signal pathway regulation and immunity.Cell Mol Life Sci2009;66:43-61

[168] Zeng ,Xiao YS.Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells.Int J Cancer2020;147:490-504

[169] Rasin MR,Breunig JJ.Numb and Numbl are required for maintenance of cadherin-based adhesion and polarity of neural progenitors.Nat Neurosci2007;10:819-27

[170] García-Heredia JM,Lucena-Cacace A,Carnero A.Numb-like (NumbL) downregulation increases tumorigenicity, cancer stem cell-like properties and resistance to chemotherapy.Oncotarget2016;7:63611-28 PMCID:PMC5325389

[171] Spana EP.Numb antagonizes Notch signaling to specify sibling neuron cell fates.Neuron1996;17:21-6

[172] Gu X,He D.Notch3 negatively regulates chemoresistance in breast cancers.Tumour Biol2016:15825-33

[173] Liang YK,Dou XW.MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines.NPJ Breast Cancer2018;4:20 PMCID:PMC6079079

[174] Lin HY,Dou XW.Notch3 inhibits epithelial-mesenchymal transition in breast cancer via a novel mechanism, upregulation of GATA-3 expression.Oncogenesis2018;7:59 PMCID:PMC6087713

[175] Wen XF,Wu Y.Inhibitor of DNA binding 2 inhibits epithelial-mesenchymal transition via up-regulation of Notch3 in breast cancer.Transl Oncol2018;11:1259-70 PMCID:PMC6097462

[176] Tan J,Xiao W.N3ICD with the transmembrane domain can effectively inhibit EMT by correcting the position of tight/adherens junctions.Cell Adh Migr2019;13:203-18 PMCID:PMC6550553

[177] Jung SG,Song JA.Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma.Cancer Sci2010;101:1977-83

[178] Gupta N,El-Sehemy A,Fu Y.Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells.Gynecol Oncol2013;130:200-6

[179] Zhou XY.TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway.Eur Rev Med Pharmacol Sci2019;23:522-9

[180] Bocci F,Tripathi SC.Numb prevents a complete epithelial-mesenchymal transition by modulating Notch signalling.J R Soc Interface2017;14:20170512 PMCID:PMC5721160

[181] Pazos MC,Bechis A.Gamma secretase inhibitor impairs epithelial-to-mesenchymal transition induced by TGF-β in ovarian tumor cell lines.Mol Cell Endocrinol2017;440:125-37

[182] Zhou J,Azad AK.Notch and TGFβ form a positive regulatory loop and regulate EMT in epithelial ovarian cancer cells.Cell Signal2016;28:838-49

[183] Lu L,Wu Y,Yang G.Rap1A promotes ovarian cancer metastasis via activation of ERK/p38 and notch signaling.Cancer Med2016;5:3544-54 PMCID:PMC5224839

[184] Yang J,Lu D.Role of Jagged1/STAT3 signalling in platinum-resistant ovarian cancer.J Cell Mol Med2019;23:4005-18 PMCID:PMC6533470

[185] Liu Z,Fu Y.NUMB knockdown enhanced the anti-tumor role of cisplatin on ovarian cancer cells by inhibiting cell proliferation and epithelial-mesenchymal transition.Translational Cancer Research2019;8:379-88

[186] Bajaj J,Vivien E.Notch signaling in CD66+ cells drives the progression of human cervical cancers.Cancer Res2011;71:4888-97

[187] Powell ME.Modern radiotherapy and cervical cancer.Int J Gynecol Cancer2010;20:S49-51

[188] Yang S,Xia B.DLL4 as a predictor of pelvic lymph node metastasis and a novel prognostic biomarker in patients with early-stage cervical cancer.Tumour Biol2016;37:5063-74

[189] Yang SS,Du YT.Inhibition of Delta-like Ligand 4 enhances the radiosensitivity and inhibits migration in cervical cancer via the reversion of epithelial-mesenchymal transition.Cancer Cell Int2020;20:344 PMCID:PMC7388465

[190] Ethier JL,Amir E.Is hormonal therapy effective in advanced endometrial cancer?.Gynecol Oncol2017;147:158-66

[191] Ramirez PT,Bodurka DC,Levenback C.Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review.Gynecol Oncol2004;95:133-8

[192] Yahata T,Tanaka K.Prediction of myometrial invasion in patients with endometrial carcinoma: comparison of magnetic resonance imaging, transvaginal ultrasonography, and gross visual inspection.Eur J Gynaecol Oncol2007;28:193-5

[193] Zhou Q,Kong D.DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma.Cancer Med2019;8:4380-8 PMCID:PMC6675747

[194] Vasiliou V,Nebert DW.Human ATP-binding cassette (ABC) transporter family.Hum Genomics2009;3:281-90 PMCID:PMC2752038

[195] Robey RW,Hall MD,Bates SE.Revisiting the role of ABC transporters in multidrug-resistant cancer.Nat Rev Cancer2018;18:452-64 PMCID:PMC6622180

[196] Housman G,Heerboth S.Drug resistance in cancer: an overview.Cancers (Basel)2014;6:1769-92 PMCID:PMC4190567

[197] Wang Z,Cao M,Huang Y.Transporter-mediated multidrug resistance and its modulation by Chinese medicines and other herbal products.Curr Drug Discov Technol2010;7:54-66

[198] Liu YP,Ger LP.Carboxyl-terminal modulator protein positively regulates Akt phosphorylation and acts as an oncogenic driver in breast cancer.Cancer Res2013;73:6194-205

[199] Abbasifarid E,Beheshtian M,Larijani B.The role of ATP-binding cassette transporters in the chemoresistance of anaplastic thyroid cancer: a systematic review.Endocrinology2019;160:2015-23

[200] Park JT,Tropè CG,Shih IeM.Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.Am J Pathol2010;177:1087-94 PMCID:PMC2928943

[201] Cho S,He X.Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells.Proc Natl Acad Sci U S A2011;108:20778-83 PMCID:PMC3251103

[202] Zhang X,Song L.ID4 promotes breast cancer chemotherapy resistance via CBF1-MRP1 pathway.J Cancer2020;11:3846-57 PMCID:PMC7171490

[203] Kim B,Hanby AM.Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy.BMC Cancer2015;15:634 PMCID:PMC4567818

[204] Bai L,Zhang Y,Zhang X.Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.Exp Cell Res2018;366:161-71

[205] Wagner W,Blauz A.The lactate receptor (HCAR1/GPR81) contributes to doxorubicin chemoresistance via ABCB1 transporter up-regulation in human cervical cancer HeLa cells.J Physiol Pharmacol2017;68:555-64

[206] Murahari M,Peters GJ.Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies.Eur J Med Chem2017;139:961-81

[207] Terek MC,Sendag F,Ozsaran A.MDR1 gene expression in endometrial carcinoma.Int J Gynecol Cancer2003;13:673-7

[208] Parks SK,Counillon L.Hypoxia promotes tumor cell survival in acidic conditions by preserving ATP levels.J Cell Physiol2013;228:1854-62

[209] Hanahan D.Hallmarks of cancer: the next generation.Cell2011;144:646-74

[210] Erin N,Brozovic A.Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.Drug Resist Updat2020;53:100715

[211] Maman S.A history of exploring cancer in context.Nat Rev Cancer2018;18:359-76

[212] Hui L,Lu G.Low dose of bisphenol a modulates ovarian cancer gene expression profile and promotes epithelial to mesenchymal transition via canonical Wnt pathway.Toxicol Sci2018;164:527-38

[213] Lin Y,Lan H.Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications.J Hematol Oncol2019;12:76 PMCID:PMC6626377

[214] Shiga K,Nagasaki T,Takahashi H.Cancer-associated fibroblasts: their characteristics and their roles in tumor growth.Cancers (Basel)2015;7:2443-58 PMCID:PMC4695902

[215] Wu P,Su M.Adaptive mechanisms of tumor therapy resistance driven by tumor microenvironment.Front Cell Dev Biol2021;9:641469 PMCID:PMC7957022

[216] Moore G,McClements L.Top Notch targeting strategies in cancer: a detailed overview of recent insights and current perspectives.Cells2020;9:1503 PMCID:PMC7349363

[217] Meurette O.Shaping of the tumor microenvironment by Notch signaling. In: Birbrair A, editor. Tumor microenvironment. Cham: Springer International Publishing; 2020. p. 1-16.

[218] Bussard KM,Stumpf K,Marini FC.Tumor-associated stromal cells as key contributors to the tumor microenvironment.Breast Cancer Res2016;18:84 PMCID:PMC4982339

[219] Fiori ME,Villanova L,Stassi G.Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance.Mol Cancer2019;18:70 PMCID:PMC6441236

[220] Xing F,Okuda H.Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain.EMBO Mol Med2013;5:384-96 PMCID:PMC3598079

[221] Zheng H,Kasimir-Bauer S.Therapeutic antibody targeting tumor- and osteoblastic niche-derived Jagged1 sensitizes bone metastasis to chemotherapy.Cancer Cell2017;32:731-47.e6 PMCID:PMC5729937

[222] Hoarau-Véchot J,Halabi N.Akt-activated endothelium promotes ovarian cancer proliferation through notch activation.J Transl Med2019;17:194 PMCID:PMC6558713

[223] Liao Z,Zhu P.Cancer-associated fibroblasts in tumor microenvironment - Accomplices in tumor malignancy.Cell Immunol2019;343:103729

[224] Tsuyada A,Wu J.CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells.Cancer Res2012;72:2768-79 PMCID:PMC3367125

[225] Studebaker AW,Werbeck JL.Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner.Cancer Res2008;68:9087-95

[226] Pelon F,Kieffer Y.Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms.Nat Commun2020;11:404 PMCID:PMC6972713

[227] Boelens MC,Nabet BY.Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways.Cell2014;159:499-513 PMCID:PMC4283810

[228] Sansone P,Rajasekhar VK.Evolution of cancer stem-like cells in endocrine-resistant metastatic breast cancers is mediated by stromal microvesicles.Cancer Res2017;77:1927-41 PMCID:PMC5392366

[229] Sun W.Role of cancer-associated fibroblasts in tumor structure, composition and the microenvironment in ovarian cancer.Oncol Lett2019;18:2173-8 PMCID:PMC6676664

[230] Zhang B,Xu Q.Revisiting ovarian cancer microenvironment: a friend or a foe?.Protein Cell2018;9:674-92 PMCID:PMC6053350

[231] Sahoo SS,Hondermarck H.The emerging role of the microenvironment in endometrial cancer.Cancers (Basel)2018;10:408 PMCID:PMC6266917

[232] Murata T,Hoffman RM.Reconstitution of a metastatic-resistant tumor microenvironment with cancer-associated fibroblasts enables metastasis.Cell Cycle2017;16:533-5 PMCID:PMC5384587

[233] Grivennikov SI,Karin M.Immunity, inflammation, and cancer.Cell2010;140:883-99 PMCID:PMC2866629

[234] Janghorban M,Rosen JM.Notch signaling as a regulator of the tumor immune response: to target or not to target?.Front Immunol2018;9:1649 PMCID:PMC6055003

[235] Hossain F,Ucar DA.Notch signaling in myeloid cells as a regulator of tumor immune responses.Front Immunol2018;9:1288 PMCID:PMC5994797

[236] Kelliher MA.NOTCH signaling in T-cell-mediated anti-tumor immunity and T-cell-based immunotherapies.Front Immunol2018;9:1718 PMCID:PMC6109642

[237] Vijayaraghavan J.Notch and T cell function - a complex tale. In: Borggrefe T, Giaimo BD, editors. Molecular mechanisms of Notch signaling. Cham: Springer International Publishing; 2018. p. 339-54.

[238] Cho OH,Miele L.Notch regulates cytolytic effector function in CD8+ T cells.J Immunol2009;182:3380-9 PMCID:PMC4374745

[239] Sugimoto K,Kitamura A.Notch2 signaling is required for potent antitumor immunity in vivo.J Immunol2010;184:4673-8

[240] Saleem SJ.Hematopoietic cytokine-induced transcriptional regulation and Notch signaling as modulators of MDSC expansion.Int Immunopharmacol2011;11:808-15 PMCID:PMC3119497

[241] Palaga T,Kueanjinda P.Notch signaling in macrophages in the context of cancer immunity.Front Immunol2018;9:652 PMCID:PMC5900058

[242] Toor SM,El Salhat H.Myeloid cells in circulation and tumor microenvironment of breast cancer patients.Cancer Immunol Immunother2017;66:753-64 PMCID:PMC5445142

[243] Peng D,Li W.Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6/STAT3 and NO/NOTCH cross-talk signaling.Cancer Res2016;76:3156-65 PMCID:PMC4891237

[244] Song JH,Park SY.Inhibitory effect of ginsenoside Rg3 on cancer stemness and mesenchymal transition in breast cancer via regulation of myeloid-derived suppressor cells.PLoS One2020;15:e0240533 PMCID:PMC7580975

[245] Liu H,Zhang M.Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.Breast Cancer Res Treat2017;166:95-107

[246] Garrido MP,Vega M.Angiogenesis in gynecological cancers: role of neurotrophins.Front Oncol2019;9:913 PMCID:PMC6761325

[247] Yetkin-Arik B,Klaassen I.Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.Biochim Biophys Acta Rev Cancer2021;1875:188446

[248] Madu CO,Madu CO.Angiogenesis in breast cancer progression, diagnosis, and treatment.J Cancer2020;11:4474-94 PMCID:PMC7255381

[249] Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW. The great escape; the hallmarks of resistance to antiangiogenic therapy.Pharmacol Rev2015;67:441-61

[250] Haibe Y,El Hajj H.Resistance mechanisms to anti-angiogenic therapies in cancer.Front Oncol2020;10:221 PMCID:PMC7056882

[251] Gacche RN.Redundant angiogenic signaling and tumor drug resistance.Drug Resist Updat2018;36:47-76

[252] Benedito R.Notch as a hub for signaling in angiogenesis.Exp Cell Res2013;319:1281-8

[253] Liu Z,Wang A,Lu Y.Dll4-Notch signaling in regulation of tumor angiogenesis.J Cancer Res Clin Oncol2014;140:525-36

[254] Akil A,Guenter R.Notch signaling in vascular endothelial cells, angiogenesis, and tumor progression: an update and prospective.Front Cell Dev Biol2021;9:642352 PMCID:PMC7928398

[255] Li JL,Oon CE.DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.Cancer Res2011;71:6073-83

[256] Yang X,Hu W,Sood AK.New ways to successfully target tumor vasculature in ovarian cancer.Curr Opin Obstet Gynecol2015;27:58-65 PMCID:PMC4529067

[257] Yeom DH,Ryu I.ABL001, a bispecific antibody targeting VEGF and DLL4, with chemotherapy, synergistically inhibits tumor progression in xenograft models.Int J Mol Sci2020;22:241 PMCID:PMC7796106

[258] Jubb AM.Biomarkers to predict the clinical efficacy of bevacizumab in cancer.Lancet Oncol2010;11:1172-83

[259] Li Y,Ambrosi DJ.ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting DLL4 and VEGF, demonstrates superior efficacy and favorable safety profiles in preclinical models.Mol Cancer Ther2018;17:1039-50

[260] Zhou R,Wen H,Wu M.The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models.Exp Cell Res2019;380:141-8

[261] Hu W,Dong HH.Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.Cancer Res2011;71:6030-9 PMCID:PMC3174342

[262] Kuhnert F,Coetzee S.Dll4 blockade in stromal cells mediates antitumor effects in preclinical models of ovarian cancer.Cancer Res2015;75:4086-96

[263] Huang J,Hu L.Dll4 inhibition plus aflibercept markedly reduces ovarian tumor growth.Mol Cancer Ther2016;15:1344-52 PMCID:PMC4893925

[264] Majidpoor J.Angiogenesis as a hallmark of solid tumors - clinical perspectives.Cell Oncol (Dordr)2021;44:715-37

[265] Li B,Ren N.Theasaponin E₁ inhibits platinum-resistant ovarian cancer cells through activating apoptosis and suppressing angiogenesis.Molecules2021;26:1681 PMCID:PMC8002815

[266] Guan L.Endostar rebuilding vascular homeostasis and enhancing chemotherapy efficacy in cervical cancer treatment.Onco Targets Ther2020;13:12811-27 PMCID:PMC7751846

[267] Coleman RL,Burger R.Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.Gynecol Oncol2020;157:386-91

[268] Jimeno A,Gordon M.A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.Invest New Drugs2019;37:461-72

[269] IeM, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy.Cancer Res2007;67:1879-82

[270] Majumder S,Golde TE,Osborne BA.Targeting Notch in oncology: the path forward.Nat Rev Drug Discov2021;20:125-44

[271] Panda M.Cell signaling and cancer: a mechanistic insight into drug resistance.Mol Biol Rep2019;46:5645-59

[272] Valcourt DM,Wang J.Nanoparticles for manipulation of the developmental Wnt, Hedgehog, and Notch signaling pathways in cancer.Ann Biomed Eng2020;48:1864-84 PMCID:PMC7196499